These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Extended radical operations on breast cancer of medial or central location.
    Author: Deemarski LYu, Seleznev IK.
    Journal: Surgery; 1984 Jul; 96(1):73-7. PubMed ID: 6740498.
    Abstract:
    Two groups of patients with central or medical primary breast cancer (T1-2N0-1M0) were studied. One group of 478 patients had an extended radical mastectomy (Urban-Kholdin) that included removal of the parasternal lymph nodes and adjoining costal cartilages. A second group of 519 concurrently treated patients had a conventional radical mastectomy (Halsted-Meyer). Among the patients who had an extended radical mastectomy, metastases were found in parasternal lymph nodes in 17.7% of those who had no metastasis in axillary or subclavicular lymph nodes, 40.9% of those who had a single metastatic focus in axillary or subclavicular lymph nodes, and 54.2% of those who had multiple axillary and/or subclavicular nodal metastases. Comparison of the two groups for the interval to tumor recurrence showed that extended radical mastectomy provided a better disease-free survivorship at both 5 and 10 years. Among patients who had an extended radical mastectomy, results at 5 years were better by 10.1% for those who had no lymph node metastases at all, better by 15.6% for those who had a single axillary or subclavicular metastasis, and better by 16.6% when multiple axillary and/or subclavicular nodal metastases were present. Follow-up at 10 and 20 years also showed a margin favoring extended radical mastectomy. Among the patients who had metastases only in parasternal lymph nodes, the disease-free survival rate was 67.4% at 5 years and 46.2% at 10 years. Extended radical mastectomy should be considered the preferred operative procedure for patients 60 years of age or younger who have primary breast cancer (T1-2N0-1M0) of central or medial origin.
    [Abstract] [Full Text] [Related] [New Search]